1<!DOCTYPE html>

Products & Services Business Operations Strategic Planning and Management

Benchmarking Advisory Board Management At Large Pharmaceutical & Medical Device Organizations

ID: PSM-319


17 Info Graphics

37 Data Graphics

500+ Metrics

3 Narratives

9 Best Practices

Pages: 66

Published: Pre-2019

Delivery Format: Shipped


License Options:

Buy Now



Pharmaceutical and medical device organizations seek strategic insights and guidance to successfully navigate the complexities of the changing healthcare landscape. An effective advisory board serves as a valuable asset that can provide informed guidance to organizations on various business aspects.

To get maximum return on investment, it is important for pharmaceutical organizations to structure their advisory boards appropriately and invest resources optimally. Best Practices, LLC recently undertook a study to assist pharmaceutical and medical device executives in identifying ways to best utilize the knowledge of advisory boards.

The study delivers leading insights and metrics on the best structure for various types of advisory boards, selection of advisory board participants, advisory board operational benchmarks and cost benchmarks for running advisory boards. It also highlights the top challenges, winning strategies and best practices for conducting advisory boards.

NOTE: Segmentation analysis was key to examining trends and effective practices. This study captures insights from the Large Companies Segment.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Medical Device; Biopharmaceutical; Academic; Research; Consulting; Biotech; Consumer Products; Education; Science; Clinical Research; Laboratories

Companies Profiled:
Abbott; Uroplasty; Avanir; Duke University and Health System; B.Braun; Haemonetics Corporation; Medicines Differentiation Analytics; Abbvie; PharMedium; Lupin; Poxel; AstraZeneca; Medunik Canada; Bayer Healthcare; MD Outlook; Acorda Therapeutics; Purdue Pharma; Biogen Idec; Reliance Institute of Life Sciences; Boehringer Ingelheim; Xenoport; cipla; Catalent Pharma Solutions; Covidien; Teva Pharmaceutical Industries Ltd; UCB Pharma; Sanofi; Novo Nordisk

Study Snapshot

This study engaged 35 executives from 29 leading life sciences companies. Segmentation analysis was key to examining trends and effective practices. Thirteen participants at 8 companies make up the Large Company Segment (annual revenues greater than USD 10 Billion). Most responses came from US & Canada(63%) followed by Asia (20%).

Key Findings

Physician & Clinical Advisory Boards Most Common: Six out of 10 benchmarked companies maintain physician and clinical advisory boards.
Segments: Large Companies utilize all the types of advisory boards studied in this research. Sixty-two percent of large companies have physician advisory boards and 69% have clinical advisory boards. Half of large companies also host marketing advisory boards.

Large Companies Prefer National Participants for Physician Advisory Boards: Unlike some benchmarked companies, 56% of large companies prefer national participants as a part of their physician advisory boards while 33% like a mix of both national and regional.

Table of Contents

Executive Summary pgs. 3-8
Research Overview pg. 3
Participating Companies pg. 4
Key Recommendations pg. 5
Segments and Abbreviations pg. 6
Key Findings & Insights pgs. 7-14

Structure Of Advisory Boards pgs. 15-23
Selection of Advisory Board Participants pgs. 24-32
Operations Of Advisory Boards pgs. 33-46
Cost Of Advisory Boards pgs. 47-53
Challenges & Best Practices pgs. 54-60
Benchmark Profile pgs. 61-64
About Best Practices, LLC pg. 65-66

List of Charts & Exhibits

7 critical steps for achieving success at advisory boards
  • Type of advisory board used by benchmark participants
  • Number of board participants
  • Factors influencing number of advisory board participants
  • Departments responsible for conducting respective advisory board meetings at participating companies
  • Length of advisory board contract
  • Preferred reach of advisory board members
  • Desired qualifications for advisory board members
  • Accepted level of education for each of the advisory board members
  • Preferred level of education for each of the advisory board members
  • Diverse set of preferred occupations for each of the advisory board member
  • Preferred level of experience (in years) in respective field for each of the advisory board member
  • Top objectives for establishing respective advisory boards (clinical, marketing, payer, physician advisory boards)
  • Number of advisory meetings conducted on an annual basis for each type of advisory board
  • Preferred duration (in hours) for each advisory board meeting
  • Total duration spent on all advisory board meetings in a year
  • Percentage for each type of advisory board meeting conducted by the organization
  • Average number of hours taken to prepare for each advisory board meeting
  • Advisory board outsourcing
  • Area of advisory board work outsourced
  • Percentage of the total budget spent on outsourcing activities
  • Budget allocated for conducting each advisory board meeting
  • Percentage spent on various parameters to conduct an advisory board meeting
  • Top challenges encountered when planning and conducting advisory boards
  • Best practices to sustain interaction and improve outcomes of advisory boards
  • Most important keys to reduce cost drivers involved in conducting advisory boards
  • Steps taken to ensure compliance with the Physician Payments Sunshine Act with respect to advisory boards